Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Currently, we are working with Orange Grove Bio and Station 41 to continue this drug development pathway. One of our therapeutic targets is renal fibrosis. To this end, Orange Grove Bio has ...

Significantly higher levels of the miRNA molecule miR-3591-5p were seen in those with CHD and moderate to severe PAH than ...

Jefferies initiated coverage of Keros Therapeutics (KROS) with a Buy rating and $107 price target The firm says Keros has expertise in the TGF-beta pathway, which plays roles in blood, lung and ...

Dysfunctional TGF-Beta is a major contributor to lung diseases ... in 2016 to develop therapeutics for targets in the Wnt pathway, a key signaling pathway that is involved in embryo development ...

For the first time, researchers have discovered that the accumulation of aged and failing cells, called senescent cells, in ...

This interesting study presents valuable information on how human cytomegalovirus (HCMV) infection disrupts the activity of the TEAD1 transcription factor, leading to widespread chromatin alterations.

SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced a strategic research collaboration with privately-held ...